DIAMOND BIOFUND INC (6901) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DIAMOND BIOFUND INC (6901) has a cash flow conversion efficiency ratio of -0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-20.80 Million ≈ $-655.41K USD) by net assets (NT$9.23 Billion ≈ $290.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DIAMOND BIOFUND INC - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how DIAMOND BIOFUND INC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 6901 liabilities breakdown for a breakdown of total debt and financial obligations.
DIAMOND BIOFUND INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DIAMOND BIOFUND INC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tonnellerie Francois Freres SA
PA:TFF
|
0.064x |
|
Hengxin Mobile Business
SHE:300081
|
-0.006x |
|
Singaraja Putra
JK:SINI
|
0.040x |
|
Worldex Industry & Trading Co. Ltd
KQ:101160
|
-0.002x |
|
Gopal Snacks Ltd
NSE:GOPAL
|
0.132x |
|
AQUILA PART PROD COM
RO:AQ
|
0.061x |
|
Sichuan Huati Lighting Tech
SHG:603679
|
-0.028x |
|
Meter Instruments Co. Ltd
SHE:301006
|
0.029x |
Annual Cash Flow Conversion Efficiency for DIAMOND BIOFUND INC (2019–2024)
The table below shows the annual cash flow conversion efficiency of DIAMOND BIOFUND INC from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see 6901 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$10.37 Billion ≈ $326.81 Million |
NT$1.14 Billion ≈ $35.89 Million |
0.110x | +821.33% |
| 2023-12-31 | NT$12.86 Billion ≈ $405.22 Million |
NT$-195.82 Million ≈ $-6.17 Million |
-0.015x | -135.56% |
| 2022-12-31 | NT$11.05 Billion ≈ $348.15 Million |
NT$473.09 Million ≈ $14.90 Million |
0.043x | +248.09% |
| 2021-12-31 | NT$10.39 Billion ≈ $327.41 Million |
NT$-300.42 Million ≈ $-9.46 Million |
-0.029x | -260.45% |
| 2020-12-31 | NT$9.10 Billion ≈ $286.71 Million |
NT$-72.99 Million ≈ $-2.30 Million |
-0.008x | +38.98% |
| 2019-12-31 | NT$3.01 Billion ≈ $94.85 Million |
NT$-39.57 Million ≈ $-1.25 Million |
-0.013x | -- |
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.